Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105316 | 1.00 | EGFR (0.71) | EGFRERBB2AURKA | |
| SCHEMBL30362981 | 1.00 | EGFR (0.71) | EGFRERBB2AURKA | |
| SCHEMBL31466883 | 1.00 | EGFR (0.71) | EGFRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL29409572 | 0.99 | EGFR (0.70) | EGFRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL30363008 | 0.99 | EGFR (0.70) | EGFRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL4997757 | 0.99 | EGFR (0.70) | EGFRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL5007769 | 0.99 | EGFR (0.70) | EGFRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL5007744 | 0.99 | EGFR (0.70) | EGFRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL20214611 | 0.99 | EGFR (0.70) | EGFRERBB2AURKA | |
| SCHEMBL5005197 | 0.96 | EGFR (0.72) | EGFRERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20220054491-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | disclosed |
| EP-3849538-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055756-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8278446-B2 | reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008073519-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | EGFR 1201/4885ERBB2 124/4885AURKA 766/4885 |
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885AURKA 852/4885 |
| US-20220054491-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885AURKA 932/4885 |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | DHPS, DPYD, DCPS | EGFR 1036/4885ERBB2 301/4885AURKA 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.